Misplaced Pages

Jane E. Henney

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (November 2011) (Learn how and when to remove this message)
Jane Henney
17th Commissioner of Food and Drugs
In office
January 17, 1999 – January 19, 2001
PresidentBill Clinton
Preceded byDavid A. Kessler
Succeeded byMark McClellan
Personal details
Born1947 (age 76–77)
Woodburn, Indiana, U.S.
EducationManchester University (B.A.)
Indiana University School of Medicine (M.D.)
University of Texas MD Anderson Cancer Center

Jane Ellen Henney (born 1947) is an American physician who was the first woman to serve as commissioner of the U.S. Food and Drug Administration. Appointed by President Bill Clinton, she served at the FDA from 1999 to 2001.

Education and career

Jane Henney was born in Woodburn, Indiana. She received her undergraduate training at Manchester University, an MD degree from Indiana University School of Medicine and did postgraduate work at the University of Texas MD Anderson Cancer Center in Houston. Trained as a medical oncologist, she joined the National Cancer Institute at the National Institutes of Health in 1976, working in the Cancer Therapy and Evaluation Program.

Prior to her appointment as commissioner, Henney had worked at the FDA from 1992 to 1994 as deputy commissioner for operations under then-commissioner David Aaron Kessler, and then at the University of New Mexico, where she was vice president of the health sciences center. After leaving the FDA she joined the board of directors of the pharmaceutical company AstraZeneca.

A significant and far reaching decision by the FDA under her tenure, was the ban on supplements and natural products that contain lovastatin, effectively handing exclusivity of cholesterol lowering compounds to pharmaceutical companies. AstraZeneca benefited directly from this decision this removed a cheap, natural product, from competing with their own statin rosuvastatin.

She was named senior vice president and provost for health affairs at the University of Cincinnati in 2003. In 2012, she was appointed to the Board of Directors of Cubist Pharmaceuticals.

References

  1. Office of the Commissioner (2022-02-28). "Jane Henney | FDA". www.fda.gov. Retrieved 2024-03-18.
  2. National Library of Medicine (14 October 2003). "Changing the Face of Medicine".
  3. "Cubist Pharmaceuticals Appoints Jane Henney to Board of Directors". www.businesswire.com. 2012-03-09. Retrieved 2024-03-18.
  • Charles Marwick, "Jane E. Henney, MD, Is New FDA Commissioner", JAMA. 1998;280:1731-1732.

External links

Library resources about
Jane E. Henney
By Jane E. Henney
Food and Drug Administration of the United States
Divisions
Major acts
Title 21 regulations and rules
Administrative lawTitle 21 of the Code of Federal Regulations (CFR)
Federal journalFederal Register (FR)
Federal lawTitle 21 of the United States Code (U.S.C.)
Commissioners
Society and culture


Flag of United StatesScientist icon

This biographical article related to a physician in the United States is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This biography of a person who has held a non-elected position in the federal government of the United States is a stub. You can help Misplaced Pages by expanding it.

Categories: